191471-52-0
191471-52-0
Chemical Structure
LY379268
- CAS No.: 191471-52-0
- Formula:C7H9NO5
- Molecular Weight:187.15
IUPAC Name: (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
InChIKey: YASVRZWVUGJELU-MDASVERJSA-N
SMILES: O=C([C@]1(N)CO[C@@]2([H])[C@H](C(O)=O)[C@@]12[H])O
Biological Activity: LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LY379268 | 99.84% | LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LY379268 (Standard) | ≥98% | LY379268 (Standard) is the analytical standard of LY379268 (HY-103558). This product is intended for research and analytical applications. LY379268 is a potent, selective and brain-penetrant mGlu2/3R agonist with EC50 values of 2.69 nM (mGlu2) and 4.48 nM (mGlu3). LY379268 has no activity on human mGlu 1a, 4a, 5a or 7a receptors. LY379268 has antioxidant and neuroprotective effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. J A Monn, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem. 1999 Mar 25;42(6):1027-40. [Content Brief]
- [2]. E F Sharpe, et al. Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. Br J Pharmacol. 2002 Mar;135(5):1255-62. [Content Brief]
Keywords
